The Xerna™ TME Panel potentially predicts response to a combination of the TLR9 agonist vidutolimod and PD-1 inhibitor pembrolizumab in metastatic melanomas with prior anti-PD-1 treatment
This poster illustrates the potential of the Xerna™ TME [...]
This poster illustrates the potential of the Xerna™ TME [...]
Rarely has a complex gene signature been successfully translated [...]
This study investigates the potential of the Xerna™ TME [...]
This study evaluates the efficacy of maintenance durvalumab in [...]
The Xerna™ TME Panel is a pan-cancer RNA-based investigational [...]
The study introduces TME Panel-1, an RNA-based diagnostic panel [...]
The study presents the development of an RNA-based diagnostic [...]